Zobrazeno 1 - 10
of 24
pro vyhledávání: '"L. L. Ilag"'
Publikováno v:
Clinical Diabetes and Endocrinology, Vol 4, Iss 1, Pp 1-11 (2018)
Abstract Background To identify baseline/clinical characteristics associated with clinically meaningful responses to insulin glargine 100 U/mL (IGlar) in insulin-naive people with type 2 diabetes mellitus (T2DM). Methods Individual participant data w
Externí odkaz:
https://doaj.org/article/9cd60482c4244802858625681dbc1178
Autor:
J K, Malone, J H Jr, Anderson, H A, Wolpert, L L, Ilag, B H, Frank, M R, De Felippis, C D, Paavola, A L, Orr, J M, Beals
Publikováno v:
Pediatric endocrinology reviews : PER. 17(Suppl 1)
Eli Lilly and Company has played a pivotal role in the development of insulin products since its discovery in 1921. Through their dedication to pharmaceutical innovation, Josiah K. Lilly Sr. and George HA Clowes, in close collaborations with the Univ
Publikováno v:
Israeli Journal of Aquaculture - Bamidgeh. 71
Fermentation-biotechnology to produce high-protein agricultural biomass with potential as a feed ingredient is well-established. However, practical applicability of this technology in aquaculture has not been fully realized. The present work evaluate
Publikováno v:
IOP Conference Series: Earth and Environmental Science. 230:012103
The wide applications of gold nanoparticles in fields such as electronics and biomedicine (targeted-drug delivery) have caught the interest of many researchers. In this study, Serratia marcescens NBL 1001 was screened for its ability to synthesize go
Autor:
J, Rosenstock, P, Hollander, A, Bhargava, L L, Ilag, R K, Pollom, J S, Zielonka, W J, Huster, M J, Prince
Publikováno v:
Diabetes, obesitymetabolism. 17(8)
To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus(®)) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D).This phase III,
Autor:
T C, Blevins, D, Dahl, J, Rosenstock, L L, Ilag, W J, Huster, J S, Zielonka, R K, Pollom, M J, Prince
Publikováno v:
Diabetes, obesitymetabolism. 17(8)
To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D).This phase III, randomized, open-label, 52-week study enrolled patients w
Autor:
R. F., Traifalgar, J., Pagapulan, M. T., Valdez, J. B., Ellamar, E. J. C., Ocampo, L. L., Ilag
Publikováno v:
Israeli Journal of Aquaculture-Bamidgeh; 2019, Vol. 71, p1-11, 11p
Autor:
Darshan S. Brar, F. Ausubel, Ning Huang, Zhikang Li, Takuji Sasaki, Masahiro Yano, Gurdev S. Khush, L. L. Ilag, D. Yang, A. Sanchez
Publikováno v:
Theoretical and Applied Genetics. 98:1022-1028
The recessive gene, xa13, confers resistance to Philippine race 6 (PXO99) of the bacterial blight pathogen Xanthomonas oryzae pv oryzae. Fine genetic mapping and physical mapping were conducted as initial steps in an effort to isolate the gene. Using
Autor:
Dieter Söll, Fernando Migliaccio, Soon-Yong Choi, Etienne Schwob, Klaus Palme, Carl R. Simmons, L L Ilag, Thomas Hesse
Publikováno v:
The Plant Journal. 4:423-432
The site I 22 kDa auxin-binding proteins from maize are encoded by a small gene family comprising at least five members. Here the cloning and molecular analysis of the Zm-ERabp1, Zm-ERabp4, and Zm-ERabp5 genes is presented. All three encode 22-23 kDa
Publikováno v:
Diabetic medicine : a journal of the British Diabetic Association. 27(5)
Self-monitoring of blood glucose (SMBG) is an important self-management tool for insulin-treated patients with Type 2 diabetes mellitus (T2DM). Its value in estimating glycaemic control in insulin-treated T2DM patients remains unclear. The relationsh